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Abstract
The human SHOX gene is composed of seven exons and encodes a paired-related homeodomain transcription factor. SHOX
mutations or deletions have been associated with different short stature syndromes implying a role in growth and bone
formation. During development, SHOX is expressed in a highly specific spatiotemporal expression pattern, the underlying
regulatory mechanisms of which remain largely unknown. We have analysed SHOX expression in diverse embryonic, fetal
and adult human tissues and detected expression in many tissues that were not known to express SHOX before, e.g. distinct
brain regions. By using RT-PCR and comparing the results with RNA-Seq data, we have identified four novel exons (exon 2a,
7-1, 7-2 and 7-3) contributing to different SHOX isoforms, and also established an expression profile for the emerging new
SHOX isoforms. Interestingly, we found the exon 7 variants to be exclusively expressed in fetal neural tissues, which could
argue for a specific role of these variants during brain development. A bioinformatical analysis of the three novel 39UTR
exons yielded insights into the putative role of the different 39UTRs as targets for miRNA binding. Functional analysis
revealed that inclusion of exon 2a leads to nonsense-mediated RNA decay altering SHOX expression in a tissue and time
specific manner. In conclusion, SHOX expression is regulated by different mechanisms and alternative splicing coupled with
nonsense-mediated RNA decay constitutes a further component that can be used to fine tune the SHOX expression level.
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Introduction
The human SHOX gene resides in the pseudoautosomal region
1 on the short arm of the X and Y chromosome. Like all genes in
the pseudoautosomal region, it escapes X inactivation and
therefore shows a ‘‘pseudo-autosomal’’ inheritance pattern [1].
SHOX encodes for a paired-related homeodomain transcription
factor. Homeodomain transcription factors are involved in the
regulation of pattern formation, differentiation and organogenesis
[2], and deficiencies in these genes can lead to a misregulation of
developmental processes resulting in malformations [3,4]. The
heterozygous loss of SHOX function due to deletions or mutations
has been shown to cause Leri-Weill Dyschondrosteosis (LWD)
while homozygous loss leads to Langer mesomelic dysplasia [5,6].
In addition, SHOX defects are a major cause of Idiopathic Short
Stature (ISS) and are involved in the etiopathology of Turner
Syndrome [7,8]. In these syndromes, SHOX defects are implicated
in inaccurate bone development and longitudinal body growth.
Studies in human and chicken revealed specific SHOX expression
in the pharyngeal arches and the early developing limbs during
embryonic and fetal development, consistent with the symptoms
seen in Turner and Langer syndrome as well as LWD [7,9].
To date, there are seven known SHOX exons encoding for two
different isoforms - SHOXa and SHOXb that employ different 39
exons (exon 6a or 6b). SHOXa and SHOXb encode proteins of 292
and 225 amino acids, respectively [1]. Alternative usage of two
different promoters (one residing in front of exon 1 and one
residing at the beginning of exon 2) leads to two mRNAs differing
in the 59UTR but generating identical proteins [10]. The
homeodomain, which is responsible for the DNA binding of this
transcription factor, is encoded by exons 3 and 4. SHOXa
encompasses an OAR domain (otp, aristaless, and rax) with a
transactivating function, while this domain is lacking in SHOXb
[1].
SHOX expression is found to be tightly regulated by different
mechanisms to obtain the SHOX specific spatio-temporal expres-
sion pattern, for example by usage of the two different promoters
[10], by enhancer regions residing up- and downstream of the
gene [11,12,13,14] and by alternative usage of the two different 39
exons [1]. In our study, we investigated if SHOX possibly features
additional coding or regulatory capacities that have not been
identified so far.
Methods
Origin of RNA and Reverse Transcription of RNA
Total RNA from various human adult tissues was purchased
from Ambion, embryonic and fetal RNA was kindly provided by
the MRC-Wellcome Trust Human Developmental Biology
Resource (HDBR, Newcastle, UK). Fetal RNA originated from
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originated from a Carnegie Stage 16 embryo.
RNA from cell lines was prepared using the illustra RNA spin
Mini Kit (GE Healthcare) according to the manufacturer’s
protocol. The following cell lines and cultured primary cells were
used: L87/4 (bone marrow fibroblasts [15]), NHDF and HDF
(primary human fibroblasts, Promocell) and Hs27 (human
fibroblasts, ATCC CRL-1634).
Reverse transcription was performed with Superscript III
Reverse Transcriptase using random hexamer and oligodT
primers (Invitrogen) with 1 mg of adult or cell line RNA. Reverse
transcription of fetal/embryonic RNA was carried out with 200 ng
RNA as a template.
Tissue screening PCRs
Screening of cDNAs for different splice variants was performed
with intron spanning exonic primers listed in Table 1. PCR
amplicons were designed to specifically detect a single SHOX
isoform at a time. PCR experiments were carried out in a 25 ml
volume with 2 ml cDNA as a template in a PTC-200 Thermo-
cycler (MJ Research). All primers were designed for an annealing
temperature of 60uC.
PCR experiments for the screening and detection of different
exons of SHOX were carried out using HotStarTaq DNA
polymerase (Qiagen) under the following conditions: initial
denaturation at 95uC for 15 min followed by 40 cycles each
consisting of 30 sec at 94uC, 30 sec at 60uC and 30–60 sec at
72uC followed by one cycle of 5 min at 72uC. For the
housekeeping gene ADP-ribosylation factor 1 (ARF1), only 35
cycles were carried out.
Resulting PCR products were checked for specificity by directly
sequencing them on a MegaBACE sequencer using the DYE-
namic ET Terminator Cycle Sequencing Kit (GE Healthcare)
according to the manufacturer’s instructions.
Rapid amplification of cDNA ends (RACE)
To determine the 39 end of novel SHOX transcripts containing
exon 7 variants, 39RACE experiments were carried out using the
GeneRacer
TM Kit (Invitrogen) according to the manufacturer’s
instructions. For the RACE-PCR, we used the following primers:
SHOXRaceEx7For 59-TTGAAAGGGGATGTGGCTTCAC-
GA-39 and SHOXRaceEx7nestedFor 59-TCTGTTATTGTC-
GGCAGGCGGTGAG-39.
Cell culture and inhibition of nonsense-mediated RNA
decay
Primary normal human dermal fibroblasts (NHDF) were
cultured in DMEM high glucose medium (Gibco/Invitrogen)
supplemented with 10% fetal bovine serum (PAA) and 1%
Penicillin/Streptomycin (Gibco/Invitrogen) at 37uC and 5% CO2.
Cells were grown to 80–90% confluence and then treated with
100 mg/ml cycloheximide (Sigma) for 6 h or 20 mM Wortmannin
(Sigma) for 2 h, respectively.
Quantitative PCR
Quantitative real-time PCR (qRT-PCR) was carried out using
the Applied Biosystems 7500 Real-Time PCR System and Absolute
SYBR Green ROX Mix (Abgene). Amplification of the exon 6a/7-
1 boundary was carried out with QuantiFast SYBR Green PCR Kit
(Qiagen). Each sample was run in duplicates. Relative levels of
mRNA expression were calculated according to the delta-delta Ct
method [16] by normalization to the expression of two different
housekeeping genes (succinate dehydrogenase complex subunit A
(SDHA) and peptidylprolyl isomerase A (PPIA)). PCR amplifications
were carried out with the following primers: SHOXafor 59-
CCTACGTCAACATGGGAGCCTTAC-39, SHOXarev 59-CC-
CGAAGGGCGGCGGG-39, PPIAfor 59-CGGGAGGCCAG-
GCTCGT-39, PPIArev 59-TGAAAGCAGGAACCCTTATAA-
CCAA-39, SDHAfor 59-TGGGAACAAGAGGGCATCTG-39,
SDHArev 59-CCACCACTGCATCAAATTCATG-39. For the
amplification of exon 2a or exon 7-1 specific products, primers
listed in Table 1 were used.
Results
Identification of novel SHOX exons
A systematic RT-PCR screen of 48 different human tissues (3
embryonic, 18 fetal and 27 adult) and four cell lines was first
carried out to analyse the expression of the known SHOX isoforms
SHOXa and SHOXb using a primer pair spanning from exon 2 to
exon 4/5 (Figure 1A). In embryonic and fetal tissue, strongest
expression was seen in muscle, skin and several neural tissues like
brain, spinal cord, eye and meninges. We also showed expression
in distinct subregions of the brain such as hindbrain (cerebellum),
thalamus and basal ganglia (Figure 2 IA). In adult tissue, strongest
expression was found in bone marrow, adipose tissue, placenta and
skeletal muscle. Similar to the findings in fetal tissue, SHOX was
also expressed in the brain (thalamus, cerebellum, frontal cortex)
(Figure 2 IIIA). SHOX expression in specific human brain regions
had not been reported before.
These RT-PCRs also revealed additional bands (e.g. in bone
marrow) that differed from the expected band size of 361 bp
(Figure 2 IIIA). Sequencing of this band indicated that 88
additional nucleotides were included into the SHOX cDNA
between exon 2 and exon 3, which we termed exon 2a, according
to the position in the cDNA (Figure 1B). Sequence and genomic
position of exon 2a is given in Figure S1. Inclusion of exon 2a into
the mRNA causes a frameshift and a premature stop codon in
exon 3. Thus, a predicted resulting protein would be truncated,
lack a homeodomain and consist of 124 amino acids (Figure 1B).
Comparison of the SHOX genomic region in different species
(UCSC browser http://genome.ucsc.edu/and ECR browser
http://ecrbrowser.dcode.org/) revealed that, unlike the formerly
known SHOX exons, the novel 88 bp exon is not conserved
between vertebrate species (data not shown).
This comparative analysis furthermore indicated an additional
conserved genomic region downstream of exon 6a. We carried out
PCR from cDNA of several tissues using a forward primer located
Table 1. Primers used for the cDNA screening for SHOX splice
variants.
Primer Name Sequence (59R39) Exon Location
SHOX Ex2 For CCGGTGCATTTGTTCAAGGA 2
SHOX Ex4/5 Rev TGCCCAAGATGACGCCTTTA 4/5
SHOX Ex2a For CGGAGATCACGGGAAGACT 2a
SHOX cDNA For ACGTCAACATGGGAGCCTTA 5
SHOX 39UTR For ACCGCTGTAAAATGACGGAG 6a
SHOX 39UTR Rev TACCCACGTGTGTCGAAGAA 7 variant 1
SHOX Ex7/2 Rev TAGGAGAATGAGGGCGTCAC 7 variant 2
SHOX Ex7new Rev1 AAGTGGAAAAACGGGTGTTG 7 variant 3
ARF For GCCAGTGTCCTTCCACCTGTC 1
ARF Rev GCCTCGTTCACACGCTCTCTG 3
doi:10.1371/journal.pone.0018115.t001
Novel SHOX Splice Variants
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spanning a genomic distance of 4193 bp. The resulting PCR
product consisted of only 256 bp and sequencing revealed that the
conserved region, that we then termed exon 7 splice variant 1 (7-1),
can be spliced directly to the 39 end of exon 6a, resulting in an
elongated 39 UTR (Figure 1C). To confirm the 39 end of this novel
SHOX splice variant, we carried out 39RACE experiments and
located the end of exon 7 at position chrX/Y: 532,318 according to
NCBI36/hg18 (data not shown).
Using primers spanning exon 5 to 7, we found another two
novel alternative 59 splice sites of exon 7 leading to two additional
SHOX isoforms (Figure 1D, 1E). These two exon 7 variants (exon
7-2 and exon 7-3) are directly attached to exon 5 and thus become
part of the open reading frame of SHOX, while exon 6 is lacking.
To verify that exon 7-2 and 7-3 are indeed part of a complete
SHOX mRNA, we carried out PCR using primers residing in exon
2 and exon 7 and were able to detect full SHOX transcripts
comprising exon 2 to 5 and the exon 7 variants (data not shown).
We therefore conclude that the four identified novel exons result
in at least four different SHOX isoforms, an overview of which is
given in Figure 1. DNA sequences, genomic positions of the novel
exons and a comparison of the amino acid sequences of the
(hypothetically) encoded protein isoforms are annotated in Figure
S1.
Screening and functional analysis of the novel splice
variants
To analyse where and when the novel SHOX splice variants are
expressed, we carried out RT-PCR from cDNAs of the 48 human
tissues described above. The exon 2a containing transcript was
detected in several fetal and adult tissues with strongest expression
in fetal eye and brain, adult bone marrow and skeletal muscle and
in most of the cell lines tested (Figure 2 IB to 2 IIIB).
The three exon 7 splice variants were expressed in several
embryonic and fetal tissues (Figure 2 I) as well as in cultured
dermal fibroblasts (NHDF, HDF and Hs27) (Figure 2 II), but not
in any of the adult tissues (Figure 2 III). Thus, these isoforms may
serve a special function during early development.
Exon 7 – the impact of alternative splicing on miRNA
binding. The 39UTR of a gene represents the main target site
for miRNAs that mediate posttranscriptional gene silencing by
annealing to specific sequences within the 39UTR of target
mRNAs [17]. Therefore, the novel exon 7 variants might comprise
additional or novel binding sequences for miRNAs that may
regulate SHOX expression. To address this issue, we carried out a
comprehensive bioinformatical analysis of the different 39UTR
sequences of the different SHOX isoforms using the miRWalk
algorithm with miRBase release 14.0 [18].
The highest absolute number of binding candidates was found
in exon 6a, which displays the longest of all known SHOX 39UTRs
(Table 2). Also the average density (average number of binding
sites per 100 bp) of predicted binding sites is comparatively high
for this exon and is only surpassed by exon 6b (Table 2). The
binding site density of exon 7-1 and 7-2 is lower than the ones of
exon 6a and 6b while exon 7-3 is comparable to exon 6a. Usage of
exon 7-2 instead of exon 6a or 6b therefore leads to transcripts
with a lower predicted miRNA binding site density. Binding sites
with a seed length longer than 10 bp (arguing for a high specificity
Figure 1. Schematic representation of known and novel SHOX splice variants. Grey depicts untranslated regions, black depicts open
reading frame. (A) SHOXa and SHOXb as described in the literature [1]. (B) Insertion of exon 2a leads to a premature stop codon in exon 3. (C) Addition
of novel exon 7 elongates the 39UTR of the SHOX transcript. (D, E) Exon 7 (with alternative 59 splice sites) can be attached directly to exon 5 and
become part of the open reading frame. Arrows represent position of primers used for the detection of the respective splice variants in the tissue
screening.
doi:10.1371/journal.pone.0018115.g001
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PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e18115Figure 2. Screening for the different SHOX transcripts. (I) Screening of fetal and embryonic tissues. (A) Detection of different SHOX
isoforms by using a forward primer situated within exon 2 and a reverse primer located at the exon junction of exons 4 and 5. Strongest expression is
seen in muscle and skin and in different parts of the brain. (B) Detection of exon 2a containing transcripts using primers situated in exon 2a and exons
4/5. Expression of this splice form is restricted to eye and brain. (C) Detection of SHOX isoforms containing exon 7-1 using primers spanning exon 6a
to exon 7-1. Expression is restricted to brain and eye. Expression in the eye varies between fetus # 1 and fetus # 2. (D) Expression of SHOX isoforms
containing exon 7-2 is restricted to embryonic hindbrain. (E) Detection of SHOX transcripts containing exon 7-3. Expression is restricted to brain and
eye and varies between fetus # 1 and fetus # 2. Exon 7-2 and exon 7-3 were detected by primer pairs spanning exon 5 to the 59ends of the
Novel SHOX Splice Variants
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3, with exon 6a exhibiting the highest number of these high seed
length predictions. This may indicate that exon 7-2 can be used to
escape the downregulation by miRNAs. An overview of predicted
binding sites for each 39UTR exon is given in Table S1. Statistical
analysis (one-way ANOVA) also indicates that the means of
binding sites are significantly different among the five SHOX
39UTR exons (p,0.001) (Table S2a). Thereafter, Student’s t-test
was performed to compare the means of all pairs with a statistical
significance level (a=0.05). The mean of binding sites of exon 6a
was found to be significantly different in a pairwise comparison
with exon 6b, exon 7-1, exon 7-2 and exon 7-3, i.e. p=0.0134,
p,0.0001, p=0.0006 and p,0.0001, respectively, suggesting a
distinct role of exon 6a in miRNA regulation (Table S2b).
Exon 2a and exon 7-1 – alternative splicing and nonsense-
mediated RNA decay. Inclusion of exon 2a into the SHOX
mRNA results in a frameshift leading to a premature termination
codon (PTC) within exon 3, which renders exon 4, 5 and 6 as part
of the 39UTR of the transcript. Messenger RNAs containing a
PTC are generally targeted for degradation by nonsense-mediated
RNA decay (NMD) [19]. This mechanism prevents the translation
of transcripts containing PTCs leading to truncated proteins or
polypeptides that are potentially noxious for the cell or the
organism. Termination codons are usually recognized as PTCs if
they are located more than 50 nt upstream of the final exon-exon
junction [20].
Besides the insertion of exon 2a, which leads to a premature
stop codon in exon 3, also the addition of exon 7-1 to the SHOXa
mRNA gives rise to an exon/exon junction more than 50 nt
downstream of the original stop codon in exon 6a, suggesting that
both isoforms could be a target of NMD.
To investigate if these two alternatively spliced isoforms are
targeted by NMD, we pharmacologically blocked the NMD
pathway and analysed whether the novel splice variants accumu-
lated in the cells. We used two different NMD-blocking drugs:
Wortmannin (WM), an inhibitor of the phosphatidylinositol 3-
kinase-related protein kinase hSMG1, which is part of the NMD
machinery [21], and Cycloheximide (CHX), an inhibitor of the
translation process [22].
To analyse the effect of blocking the NMD pathway, NHDF
primary cells and Hs27 cells were treated with CHX or WM or
left untreated. We then analyzed the expression levels of the exon
2a and exon 7-1 containing SHOX isoforms by qRT-PCR
(Figure 3). The isoform containing exon 2a could be detected in
both cell lines. Treatment with either WM or CHX led to an
increase of exon 2a containing mRNA in NHDF and Hs27 cells,
indicating that this isoform is normally degraded by NMD
(Figure 3A and B, left graph). To confirm the specific effect of
CHX and WM treatment, we also evaluated the expression level
of the most prominent isoform, SHOXa, which does not contain a
PTC (Figure 3 A, middle graph, and 3 B, right graph). In Hs27
cells, the SHOXa level remained unaltered upon WM or CHX
treatment (Figure 3A, middle graph), indicating a very specific
effect of CHX and WM on RNA containing SHOX exon 2a in
this cell line. In NHDF cells, addition of CHX, but not of WM
led to an increase of the SHOXa expression level (Figure 3 B, right
graph) indicating a slightly unspecific reaction upon CHX
treatment. However, the increase seen for SHOX Exon 2a was
to a considerable degree higher (32.2x vs. 4.1x). Thus, we assume
that, even when taking into consideration some unspecific CHX
effect, CHX leads to a specific inhibition of NMD of the exon 2a
containing SHOX isoform. Our data derived from Hs27 and
NHDF cells therefore argue for a depletion of the exon 2a
containing isoform by NMD.
As the expression level of the exon 7-1 containing isoform was
not sufficient for reliable detection by qRT-PCR in NHDF, we
analyzed this isoform only in Hs27 cells. NMD inhibition by WM
or CHX failed to increase the level of exon 7-1 containing mRNA
(Figure 3 A, right graph), suggesting that despite the presence of a
PTC this isoform is not subjected to NMD.
Discussion
SHOX expression pattern and identification of novel
SHOX exons
We have analysed the expression pattern of the SHOX gene by
RT-PCR in a variety of embryonic, fetal and adult tissues and
cell lines. Besides the known SHOX expression in tissues involved
in body growth such as chondrocytes and cartilage, SHOX is
expressed in various other additional tissues, e.g. in different fetal
and adult brain regions such as hindbrain (cerebellum), thalamus
and basal ganglia, pointing to an additional function of SHOX
during fetal brain development and maintenance of brain
functions. However, obvious brain malformations or cognitive
developmental delay have not been described in patients with
LWD, Turner or Langer syndrome or ISS patients with SHOX
haploinsufficiency. We therefore speculate that SHOX2, a highly
related SHOX paralogue [23] that is also expressed in the brain,
may partly take over the functions of SHOX in the developing
brain in these patients. Support for this hypothesis comes from
the expression patterns of these two genes in chicken brain where,
Table 2. Overview of SHOX exon lengths and number of
predicted miRNA binding sites.
Exon
Length of
Exon (bp)
Total number of
predicted binding sites
Binding
site density
6a 2433 329 13.5
6b 627 108 17.2
7-1 823 62 7.5
7-2 337 29 8.6
7-3 1642 219 13.3
Binding site density is calculated as the average number of predicted miRNA
binding sites per 100 bp.
doi:10.1371/journal.pone.0018115.t002
respective variants of exon 7. (F) Expression of the housekeeping gene ARF1 was used to indicate similar mRNA levels. (II) Screening of cell lines
and cultured cells that show SHOX expression. L87/4 bone marrow stromal cell line; NHDF normal human dermal fibroblast primary cells; HDF
human dermal fibroblast primary cells; Hs27 diploid human fibroblasts. (A) All fibroblasts tested express SHOX at different levels. (B, C, D) Primary
cultured fibroblasts express different SHOX isoforms containing exon 2a, exon 7-1 and exon 7-2, respectively. (E) The exon 7-3 containing isoform is
absent in all cells tested. (F) Expression of the housekeeping gene ARF1 was used to indicate similar mRNA levels. (III) Screening of adult tissues.
(A) SHOX is expressed in a variety of tissues with strongest expression in placenta, skeletal muscle, bone marrow and adipose tissue. SHOX is also
expressed in various brain tissues tested. (B) Detection of transcripts that include exon 2a. Expression is found in skeletal muscle and bone marrow
and also weakly in the cerebellum and frontal cortex. (C–E) Detection of isoforms containing the different exon 7 variants; expression was not found
for any of the tissues tested. (F) Expression of the housekeeping gene ARF1 was used to indicate similar mRNA levels.
doi:10.1371/journal.pone.0018115.g002
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orthologue in rodents). Whereas SHOX/Shox and SHOX2/Shox2
expression patterns only partially overlap in the developing limb
[7] [9], the area of Shox expression is completely covered by the
broader Shox2 expression pattern in the developing chicken brain
(Figure S2).
We have identified four novel SHOX exons, which create new
coding and untranslated regions. Similar to the known isoforms
SHOXa and SHOXb with important functions during limb
development, most of the novel splice variants are only expressed
very weakly in most tissues. This low expression abundance is a
feature of many transcription factors that need to recognize the
correct target sites within the genome and to react to regulatory
events [24].
Exons 2a and 7 were identified by RT-PCR and validated by
subsequent sequencing. To also confirm these data by RNA-
Sequencing (RNA-Seq), we searched published RNA-Seq data
[25,26,27], and data integrated into the UCSC browser
NCBI36/hg18 (Burge RNA-Seq [28], CSHL Long RNA-Seq,
GIS RNA-Seq, Caltech RNA-Seq and Helicos RNA-Seq) that
had been performed on 11 tissues and 15 cell lines including
those known by RT-PCR to express novel SHOX exons. These
data showed very low densities of mapped reads in the whole
SHOX genomic region probably due to the low expression level
of SHOX in tested cells and tissues and did not provide
conclusive information about known or novel SHOX isoforms.
As SHOX expression is comparatively higher in human
fibroblasts (Figure 2), we further analysed an RNA-Seq dataset
of Hs27 human fibroblast cells (Irena Vlatkovic and Denise
Barlow, unpublished data; manuscript in preparation). This
Hs27 RNA-Seq showed expression of known SHOX exons and
exons 2a and 7 (data not shown) further validating the existence
of the novel exons.
The exon 2a containing isoform is expressed in both fetal and
adult tissues whereas all exon 7 containing isoforms are present in
fibroblasts but otherwise restricted to embryonic and fetal stages,
pointing to a likely role of exon 7 during early development.
Alternative splicing as a possibility to regulate gene
expression
Alternative splicing does not only increase the proteome of an
organism [28], but also contributes to the complex regulation of
the levels and tissue specificity of gene expression (for a review on
the different splicing mechanisms see [29]). Based on our results,
we suggest that the alternative splicing of the SHOX gene
principally exerts regulatory functions. First, SHOX possesses two
different promoters that generate transcripts with identical coding
capacity but differing in the 59UTR leading to different
translational efficiencies of the transcript [10]. Second, SHOX is
known to be expressed as two alternative isoforms, SHOXa and
SHOXb (Figure 1A), with the latter lacking the OAR domain with
a supposed transactivating function. The SHOXb protein might
therefore act as a regulatory modulator of SHOXa activity [30].
Third, we have now identified additional SHOX isoforms, which
are all likely to be involved in the fine tuning of the regulation of
SHOX expression. The novel SHOX isoforms containing exon 7-2
or 7-3 do not encode for an OAR domain and thus might also
exert a regulatory role by modulating SHOXa activity.
The three exon 7 isoforms could also exhibit novel binding sites
for miRNAs. As the majority of validated mRNA-miRNA
interactions usually takes place in the 39UTR of a gene [31], we
have analysed the 39UTRs of the different SHOX splice variants
for miRNA binding sites by the miRWalk prediction tool. The
absolute number of predicted binding sites is highest in exon 6a,
which gives rise to the longest SHOX 39UTR known to date, while
the binding site density is highest in exon 6b. Long 39UTRs and
high binding site densities are characteristic for genes whose
expression is regulated by miRNAs [32]. Exon 6a also contains the
highest number of sequence motifs where binding was predicted to
occur with a seed length longer than 10 bp, and statistical analyses
showed that the means of binding sites in this exon is significantly
different from the other SHOX 39UTR exons. miRNA regulation
of SHOX might therefore open up additional possibilities for the
fine tuning of SHOX expression, and we assume that this
Figure 3. Effect of NMD inhibition on the expression levels of different SHOX isoforms. (A) Expression levels in Hs27 cells. Left: The relative
amount of exon 2a containing mRNA in HS27 cells increases after NMD inhibition by CHX or WM. Middle: After addition of CHX or WM, SHOXa levels
remain unchanged. Right: Addition of WM does not change the expression level of exon 7-1 containing mRNA; addition of CHX leads to a decrease of
expression. (B) Expression levels in NHDF cells. Left: The relative amount of exon 2a containing mRNA in NHDF increases after NMD inhibition by CHX
or WM. Right: After addition of WM, SHOXa levels remain unchanged; addition of CHX leads to a slight increase of SHOX (4.1x). However, in
comparison to the increase seen for exon 2a (32.2x), this increase is negligible. Relative expression levels of untreated cells were always set to one.
doi:10.1371/journal.pone.0018115.g003
Novel SHOX Splice Variants
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likely by the exon 7 variants. Interestingly, we found exon 7
variants to be exclusively expressed in fetal neural tissues (Figure 2),
suggesting that these variants might be of special importance
during early brain development.
Inclusion of exon 2a into the SHOX mRNA leads to a transcript
with a premature stop codon that most likely does not encode for a
functional protein but undergoes degradation by nonsense-mediat-
ed RNA decay (Figure 3). Premature stop codons lead to NMD and
can be generated by point or frameshift mutations, but also by
alternative splicing, e.g. by inclusion/skipping of exons (as it is seen
for SHOX exon 2a), by usage of alternative splice sites or by addition
of a 39UTR exon that leads to an exon/exon junction more than
50 ntdownstream oftheoriginalstopcodon (asseenforSHOXexon
7-1), which will then be recognized as premature [33].
Whereas we provide evidence for a degradation of the exon 2a
containing SHOX isoform, the isoform containing exon 7-1 most
likely escapes the degradation by NMD despite the presence of a
PTC according to the 50 nt rule. NMD-resistant PTC-containing
mRNAs have been previously reported for several genes, including
b-globin and the familial Mediterranean fever gene [34,35]. The
definite mechanism that confers NMD-resistance still remains
unanswered although it has been suggested that spatial rearrange-
ments of the 39UTR that affect the distance between PTC and
poly(A) tail can modulate the NMD pathway [36]. The coupling of
alternative splicing and NMD is a previously described phenomenon
[e.g. 35,37], which is now also demonstrated for the SHOX gene for
the exon 2a containing isoform. However, it is controversial whether
the occurrence of the alternatively spliced products reflects
constitutive unproductive splicing, hence cellular noise, or if this
process provides an additional level of regulation to help the cell to
achieve the proper level of expression for a given protein [33,38]. If
the first hypothesis is true, it would mean that the ratio of mRNAs
encoding the functional or the non-functional protein is not
significantly variable but that a certain amount of pre-mRNA is
always spliced unproductively. A comparison of the expression of
total SHOX mRNA with the expression of exon 2a containing
mRNA (Figure 2 I-III A, B) clearly shows that this is not the case for
SHOX. In fetal eye and brain, relatively high amounts of SHOX are
detectable and there is also a detectable amount of the alternative
exon 2a containing transcript, while this is not the case for e.g. fetal
muscle or spinal cord, thus arguing for tissue-specific alternative
splicingevents.Thistimeandtissuedependentspecificsplicingmight
be caused by the presence of different regulatory splicing factors that
act in a manner autologous to transcription factors to down-regulate
the expression of a gene by alternatively splicing the pre-mRNA to a
product that undergoes NMD (also described in [39]).
Taken together, our results add important novel aspects to the
complex regulation of the SHOX gene. In addition to two
alternative promoters [10] and enhancers up- and downstream
of the gene [11,12,13,14], we have revealed that alternative
splicing coupled with NMD can also contribute to the time and
tissue specific regulation of SHOX expression and that usage of
different 39UTRs might also be involved in SHOX regulation.
Only the orchestrated interaction of the different regulatory
components ensures the accurate expression of SHOX during limb
and brain development and in mature organisms.
Supporting Information
Figure S1 Novel SHOX exons and isoforms – important
features. (A) DNA sequence and genomic location of the
novel SHOX exons. Capital letters indicate exonic sequence,
small letters indicate flanking intronic sequence. For exon 7-2 and
7-3, letters in bold print indicate coding sequences, normal letters
indicate 39UTR. Genomic position according to NCBI36/hg18.
(B) Exon-wise comparison of the protein sequences of the
different SHOX isoforms. The protein sequence of the exon
7-1 containing SHOX isoform is identical to SHOXa and
therefore not included into the comparison.
(TIF)
Figure S2 Adjacent transverse sections of a d6 chicken
head as exemplary illustration of Shox and Shox2
expression in the developing chicken brain. Shox2 is
strongly expressed in the dorsal root ganglia and in the
diencephalon, whereas Shox expression is only seen in the
diencephalon and completely covered by Shox2 expression. drg,
dorsal root ganglia; de, diencephalon; le, left eye; re, right eye.
Arrows indicate specific Shox/Shox2 expression. chShox riboprobes
were generated and digoxigenin labelled by in vitro transcription
of a PCR product amplified using the following primers out of
chicken cDNA: chiSHOX_1_For gagcttgggaactccgatt and
chiSHOX_2_Rev ttcagacagtcccagcctct. In situ hybridizations on
tissue sections were carried out as described in Decker et al. 2011.
Reference Figure S2 Decker E, Durand C, Bender S, Roedel-
sperger C, Glaser A, Hecht J, Schneider KU, Rappold G (2011).
FGFR3 is a target of the homeobox transcription factor SHOX in
limb development. Hum Mol Genet. doi:10.1093/hmg/ddr030.
(TIF)
Table S1 Overview of predicted miRNA binding sites
within the different 39 exons of SHOX. For each exon, name,
position and seed length of each miRNA predicted to bind are given.
(XLS)
Table S2 Statistical analyses of miRNA binding site
predictions. (A) Overview of statistical analysis of one-way
ANOVA on SHOX exons. (B) Overview of comparisons of means
for each pair using Student’s t-test (t=1.96423 and a=0.05).
(XLS)
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